Molecular determinants of Alzheimer's disease Aβ peptide neurotoxicity

Future Neurology

Volumn 2, Issue 4, 2007, Pages 397-409

  Cappai, Roberto ^a,b   Barnham, Kevin J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

A ; Alzheimer's disease; Amyloid; Metal; Neurodegeneration; Oligomer; Oxidative stress; Synapse; Tau; Toxicity

Indexed keywords

1,1' XYLYLBIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ALPHA SECRETASE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; ASCORBIC ACID; BETA SECRETASE; CHELATING AGENT; CLIOQUINOL; COPPER ION; CURCUMIN; CYCLAM DERIVATIVE; DP 109; GINKGO BILOBA EXTRACT; GOSSYPINE; JKL 169; MELATONIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; TRIENTINE; UNCLASSIFIED DRUG; ZINC;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CELL DEATH; CLINICAL TRIAL; CROSS LINKING; HUMAN; LONG TERM POTENTIATION; METAL BINDING; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SYNAPSE; WILSON DISEASE;

EID: 34447345723     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.2.4.397     Document Type: Review

References (126)

1. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580), 353-356 (2002).
2. Masters CL, Cappai R, Barnham KJ, Villemagne VL: Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J. Neurochem. 97(6), 1700-1725 (2006).
3. Kang J, Lemaire H, Unterbeck A et al.: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325(6106), 733-736 (1987).
4. Haass C, Schlossmacher MG, Hung AY et al.: Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-325 (1992).
5. Jarrett JT, Berger EP, Lansbury PT Jr: The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32(18), 4693-4697 (1993).
6. Liao MQ, Tzeng YJ, Chang LY et al.: The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Aβ peptides. FEBS Lett. 581(6), 1161-1165 (2007).
7. Yankner BA, Duffy LK, Kirschner DA: Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 250(4978), 279-282 (1990).
8. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW: Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13(4), 1676-1687 (1993).
9. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW: In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563(1-2), 311-314 (1991).
10. Pike CL, Walencewicz AJ, Glabe CG, Cotman CW: Aggregation-related toxicity of synthetic β-amyloid protein in hippocampal cultures. Eur. J. Pharmacol. 207(4), 367-368 (1991).
11. Walsh DM, Klyubin I, Fadeeva JV et al.: Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (6880), 535-539 (2002).
12. Lambert MP, Barlow AK, Chromy BA et al.: Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95(11), 6448-6453 (1998).
13. 2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-β peptide. Biochemistry 46(10), 2881-2891 (2007).
14. Barghorn S, Nimmrich V, Striebinger A et al.: Globular amyloid β-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 95(3), 834-847 (2005).
15. Lesne S, Koh MT, Kotilinek L et al.: A specific amyloid-β protein assembly in the brain impairs memory. Nature 440(7082), 352-357 (2006).
16. McLean CA, Cherny RA, Fraser FW et al.: Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (6), 860-866 (1999).
17. Lue LF, Kuo YM, Roher AE et al.: Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155(3), 853-862 (1999).
18. Wang J, Dickson DW, Trojanowski JQ, Lee VM: The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158(2), 328-337 (1999).
19. Naslund J, Haroutunian V, Mohs R et al.: Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283(12), 1571-1577 (2000).
20. Yun SH, Gamkrelidze G, Stine WB et al.: Amyloid-β1-42 reduces neuronal excitability in mouse dentate gyrus. Neurosci. Lett. 403(1-2), 162-165 (2006).
21. Klyubin I, Walsh DM, Cullen WK et al.: Soluble arctic amyloid β protein inhibits hippocampal long-term potentiation in vivo. Eur. J. Neurosci. 19(10), 2839-2846 (2004).
22. Klyubin I, Walsh DM, Lemere CA et al.: Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11(5), 556-561 (2005).
23. Trommer BL, Shah C, Yun SH et al.: ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-β1-42. Neurobiol. Dis. 18(1), 75-82 (2005).
24. Wang HW, Pasternak JF, Kuo H et al.: Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924(2), 133-140 (2002).
25. Chen QS, Kagan BL, Hirakura Y, Xie CW: Impairment of hippocampal long-term potentiation by Alzheimer amyloid β-peptides. J. Neurosci. Res. 60(1), 65-72 (2000).
26. Cleary JP, Walsh DM, Hofmeister JJ et al.: Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 8(1), 79-84 (2005).
27. Small DH, Mok SS, Bornstein JC: Alzheimer's disease and Aβ toxicity: from top to bottom. Nat. Rev. Neurosci. 2(8), 595-598 (2001).
28. Puzzo D, Palmeri A, Arancio O: Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease. Rev. Neurosci. 17(5), 497-523 (2006).
29. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R: Block of long-term potentiation by naturally secreted and synthetic amyloid β-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 24(13), 3370-3378 (2004).
30. Minogue AM, Schmid AW, Fogarty MP et al.: Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-β on long term potentiation and cell death in hippocampus: a role for interleukin-1β? J. Biol. Chem. 278(30), 27971-27980 (2003).
31. Chong YH, Shin YJ, Lee EO et al.: ERK1/2 activation mediates Aβ oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J. Biol. Chem. 281(29), 20315-20325 (2006).
32. Chin J, Palop JJ, Yu GQ et al.: Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J. Neurosci. 24(19), 4692-4697 (2004).
33. Braithwaite SP, Paul S, Nairn AC, Lombroso PJ: Synaptic plasticity: one STEP at a time. Trends Neurosci. 29(8), 452-458 (2006).
34. Snyder EM, Nong Y, Almeida CG et al.: Regulation of NMDA receptor trafficking by amyloid-β. Nat. Neurosci. 8(8), 1051-1058 (2005).
35. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A: Tau is essential to β-amyloid-induced neurotoxicity. Proc. Natl Acad. Sci. USA 99(9), 6364-6369 (2002).
36. Sengupta A, Novak M, Grundke-Iqbal I, Iqbal K: Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Lett. 580(25), 5925-5933 (2006).
37. Gotz J, Chen F, van Dorpe J, Nitsch RM: Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ 42 fibrils. Science 293(5534), 1491-1495 (2001).
38. Lewis J, Dickson DW, Lin WL et al.: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293(5534), 1487-1491 (2001).
39. Roberson ED, Scearce-Levie K, Palop JJ et al.: Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316(5825), 750-754 (2007).
40. Lin H, Bhatia R, Lal R: Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J. 15(13), 2433-2444. (2001).
41. Ambroggio EE, Kim DH, Separovic F et al.: Surface behavior and lipid interaction of Alzheimer β-amyloid peptide 1-42: a membrane-disrupting peptide. Biophys. J. 88(4), 2706-2713 (2005).
42. Bhatia R, Lin H, Lal R: Fresh and globular amyloid β protein (1-42) induces rapid cellular degeneration: evidence for AβP channel-mediated cellular toxicity. FASEB J. 14(9), 1233-1243. (2000).
43. Lau TL, Ambroggio EE, Tew DJ et al.: Amyloid-β peptide disruption of lipid membranes and the effect of metal ions. J. Mol. Biol. 356(3), 759-770 (2006).
44. Holscher C: Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol. Dis. 5(3), 129-141 (1998).
45. Kourie JI, Henry CL, Farrelly P: Diversity of amyloid β protein fragment [1-40]-formed channels. Cell. Mol. Neurobiol. 21(3), 255-284 (2001).
46. Demuro A, Mina E, Kayed R et al.: Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280(17), 17294-17300 (2005).
47. Kayed R, Head E, Thompson JL et al.: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300(5618), 486-489 (2003).
48. Kourie JI, Culverson AL, Farrelly PV, Henry CL, Laohachai KN: Heterogeneous amyloid-formed ion channels as a common cytotoxic mechanism: implications for therapeutic strategies against amyloidosis. Cell Biochem. Biophys. 36(2-3), 191-207 (2002).
49. Verdier Y, Zarandi M, Penke B: Amyloid β-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J. Pept. Sci. 10(5), 229-248 (2004).
50. Yan SD, Chen X, Fu J et al.: RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691 (1996).
51. Arancio O, Zhang HP, Chen X et al.: RAGE potentiates Aβ-induced perturbation of neuronal function in transgenic mice. EMBO J. 23(20), 4096-4105 (2004).
52. Shibata M, Yamada S, Kumar SR et al.: Clearance of Alzheimer's amyloid-β(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106(12), 1489-1499 (2000).
53. Deane R, Wu Z, Sagare A et al.: LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 43(3), 333-344 (2004).
54. De Felice FG, Velasco PT, Lambert MP et al.: Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor- dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282(15), 11590-11601 (2007).
55. Sabo S, Lambert MP, Kessey K et al.: Interaction of β-amyloid peptides with integrins in a human nerve cell line. Neurosci. Lett. 184, 25-28 (1995).
56. Bi X, Gall CM, Zhou J, Lynch G: Uptake and pathogenic effects of amyloid β peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience 112(4), 827-840 (2002).
57. Coulson EJ: Does the p75 neurotrophin receptor mediate Aβ-induced toxicity in Alzheimer's disease? J. Neurochem. 98(3), 654-660 (2006).
58. Zhang Y, Hong Y, Bounhar Y et al.: p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid β peptide cytotoxicity. J. Neurosci. 23(19), 7385-7394 (2003).
59. Perini G, Della-Bianca V, Politi V et al.: Role of p75 neurotrophin receptor in the neurotoxicity by β-amyloid peptides and synergistic effect of inflammatory cytokines. J. Exp. Med. 195(7), 907-918 (2002).
60. Crouch PJ, Blake R, Duce JA et al.: Copper-dependent inhibition of human cytochrome C oxidase by a dimeric conformer of amyloid-β1-42. J. Neurosci. 25(3), 672-679 (2005).
61. Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK: Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci. 26(35), 9057-9068 (2006).
62. Manczak M, Anekonda TS, Henson E et al.: Mitochondria are a direct site of Aβ accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 15(9), 1437-1449 (2006).
63. Caspersen C, Wang N, Yao J et al.: Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 19(14), 2040-2041 (2005).
64. Lustbader JW, Cirilli M, Lin C et al.: ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease. Science 304(5669), 448-452 (2004).
65. Takuma K, Yao J, Huang J et al.: ABAD enhances Aβ-induced cell stress via mitochondrial dysfunction. FASEB J. 19(6), 597-598 (2005).
66. White AR, Guirguis R, Brazier MW et al.: Sublethal concentrations of prion peptide PrP106-126 or the amyloid β peptide of Alzheimer's disease activates expression of proapoptotic markers in primary cortical neurons. Neurobiol. Dis. 8(2), 299-316 (2001).
67. Ivins KJ, Bui ET, Cotman CW: β-amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis. Neurobiol. Dis. 5(5), 365-378 (1998).
68. Nakagawa T, Zhu H, Morishima N et al.: Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature 403(6765), 98-103 (2000).
69. Casas C, Sergeant N, Itier JM et al.: Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 165(4), 1289-1300 (2004).
70. Gomez-Ramos P, Asuncion Moran M: Ultrastructural localization of intraneuronal Aβ-peptide in Alzheimer disease brains. J. Alzheimers Dis. 11(1), 53-59 (2007).
71. Wegiel J, Kuchna I, Nowicki K et al.: Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. Acta Neuropathol. (Berl.) 113(4), 389-402 (2007).
72. Sengupta P, Garai K, Sahoo B et al.: The amyloid β peptide (Aβ(1-40)) is thermodynamically soluble at physiological concentrations. Biochemistry 42(35), 10506-10513 (2003).
73. Bush AI: The metallobiology of Alzheimer's disease. Trends Neurosci. 26(4), 207-214 (2003).
74. Atwood CS, Moir RD, Huang X et al.: Dramatic aggregation of Alzheimer aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273 (21), 12817-12826. (1998).
75. Huang X, Atwood CS, Moir RD et al.: Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's AΒ peptides. J. Biol. Inorg. Chem. 9(8), 954-960 (2004).
76. Butterfield DA, Perluigi M, Sultana R: Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur. J. Pharmacol. 545(1), 39-50 (2006).
77. Behl C, Davis JB, Lesley R, Schubert D: Hydrogen peroxide mediates amyloid β protein toxicity. Cell 77(6), 817-827 (1994).
78. Cuajungco MP, Goldstein LE, Nunomura A et al.: Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of aβ by zinc. J. Biol. Chem. 275(26), 19439-19442 (2000).
79. Huang X, Atwood CS, Hartshorn MA et al.: The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal reduction. Biochemistry 38 (24), 7609-7616 (1999).
80. Huang X, Cuajungco MP, Atwood CS et al.: Cu(II) potentiation of alzheimer aβ neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274(52), 37111-37116. (1999).
81. Smith DP, Smith DG, Curtain CC et al.: Copper-mediated amyloid-β toxicity is associated with an intermolecular histidine bridge. J. Biol. Chem. 281(22), 15145-15154 (2006).
82. Milton NG: Amyloid-β binds catalase with high affinity and inhibits hydrogen peroxide breakdown. Biochem. J. 344(Pt 2), 293-296 (1999).
83. Barnham KJ, Ciccotosto GD, Tickler AK et al.: Neurotoxic, redox-competent Alzheimer's β-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 278(44), 42959-42965 (2003).
84. Ciccotosto GD, Tew D, Curtain CC et al.: Enhanced toxicity and cellular binding of a modified amyloid β peptide with a methionine to valine substitution. J. Biol. Chem. 279(41), 42528-42534 (2004).
85. Ali FE, Separovic F, Barrow CJ et al.: Methionine regulates copper/ hydrogen peroxide oxidation products of Aβ. J. Pept. Sci. 11(6), 353-360 (2005).
86. Schiewe AJ, Margol L, Soreghan BA, Thomas SN, Yang AJ: Rapid characterization of amyloid-β side-chain oxidation by tandem mass spectrometry and the scoring algorithm for spectral analysis. Pharm. Res. 21(7), 1094-1102 (2004).
87. Curtain CC, Ali F, Volitakis I et al.: Alzheimer's disease amyloid-β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276(23), 20466-20473. (2001).
88. Butterfield DA, Griffin S, Munch G, Pasinetti GM: Amyloid β-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J. Alzheimers Dis. 4(3), 193-201 (2002).
89. Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA: Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's Aβ(1-42) and Aβ (25-35). J. Am. Chem. Soc. 123(24), 5625-5631 (2001).
90. Pogocki D, Schoneich C: Redox properties of Met(35) in neurotoxic β-amyloid peptide. A molecular modeling study. Chem. Res. Toxicol. 15(3), 408-418 (2002).
91. Naslund J, Schierhorn A, Hellman U et al.: Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl Acad. Sci. USA 91(18), 8378-8382 (1994).
92. Kuo YM, Kokjohn TA, Beach TG et al.: Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 276(16), 12991-12998. (2001).
93. Dong J, Atwood CS, Anderson VE et al.: Metal binding and oxidation of amyloid-β within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42(10), 2768-2773 (2003).
94. Butterfield DA: Amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic. Res. 36(12), 1307-1313 (2002).
95. Varadarajan S, Yatin S, Kanski J, Jahanshahi F, Butterfield DA: Methionine residue 35 is important in amyloid β-peptide-associated free radical oxidative stress. Brain Res. Bull. 50(2), 133-141 (1999).
96. Bitan G, Tarus B, Vollers SS et al.: A molecular switch in amyloid assembly: Met35 and amyloid β-protein oligomerization. J. Am. Chem. Soc. 125(50), 15359-15365 (2003).
97. Chen K, Kazachkov M, Yu PH: Effect of aldehydes derived from oxidative deamination and oxidative stress on β-amyloid aggregation; pathological implications to Alzheimer's disease. J. Neural Transm. 114(6), 835-839 (2007).
98. Ali FE, Barnham KJ, Barrow CJ, Separovic F: Metal catalyzed oxidation of tyrosine residues by different oxidation systems of copper/hydrogen peroxide. J. Inorg. Biochem. 98(1), 173-184 (2004).
99. Metodiewa D: Molecular mechanisms of cellular injury produced by neurotoxic amino acids that generate reactive oxygen species. Amino Acids 14(1-3), 181-187 (1998).
100. Leeuwenburgh C, Hansen PA, Holloszy JO, Heinecke JW: Hydroxyl radical generation during exercise increases mitochondrial protein oxidation and levels of urinary dityrosine. Free Radic. Biol. Med. 27(1-2), 186-192 (1999).
101. Lovell MA, Xie C, Markesbery WR: Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 51(6), 1562-1566 (1998).
102. Atwood CS, Perry G, Zeng H et al.: Copper mediates dityrosine cross-linking of Alzheimer's amyloid-β. Biochemistry 43(2), 560-568 (2004).
103. 2. J. Biol. Chem. 277(43), 40302-40308 (2002).
104. Barnham KJ, Haeffner F, Ciccotosto GD et al.: Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease β-amyloid. FASEB J. 18(12), 1427-1429 (2004).
105. Malencik DA, Anderson SR: Dityrosine as a product of oxidative stress and fluorescent probe. Amino Acids 25(3-4), 233-247 (2003).
106. Roher A, Wolfe D, Palutke M, KuKuruga D: Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. Proc. Natl Acad. Sci. USA 83(8), 2662-2666 (1986).
107. Zandi PP, Anthony JC, Khachaturian AS et al.: Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 61(1), 82-88 (2004).
108. Yoon I, Lee KH, Cho J: Gossypin protects primary cultured rat cortical cells from oxidative stress- and β-amyloid-induced toxicity. Arch. Pharm. Res. 27(4), 454-459 (2004).
109. Zatta P, Tognon G, Carampin P: Melatonin prevents free radical formation due to the interaction between β-amyloid peptides and metal ions (Al[III], Zn[II], Cu[II], Mn[II], Fe[II]). J. Pineal Res. 35(2), 98-103 (2003).
110. Feng Z, Chang Y, Cheng Y et al.: Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J. Pineal Res. 37(2), 129-136 (2004).
111. Defeudis FV: Bilobalide and neuroprotection. Pharmacol. Res. 46(6), 565-568 (2002).
112. Schneider LS, DeKosky ST, Farlow MR et al.: A randomized, double-blind, placebo-controlled trial of two doses of ginkgo biloba extract in dementia of the Alzheimer's type. Curr. Alzheimer Res. 2(5), 541-551 (2005).
113. Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H: The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 67(9 Suppl. 3), S6-S11 (2006).
114. Kim DS, Park SY, Kim JK: Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βA(1-42) insult. Neurosci. Lett. 303(1), 57-61 (2001).
115. Ono K, Hasegawa K, Naiki H, Yamada M: Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro. J. Neurosci. Res. 75(6), 742-750 (2004).
116. Yang F, Lim GP, Begum AN et al.: Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280 (7), 5892-5901 (2005).
117. Baum L, Ng A: Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis. 6(4), 367-377 (2004).
118. Moret V, Laras Y, Pietrancosta N et al.: 1,1′-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution. Bioorg. Med. Chem. Lett. 16(12), 3298-3301 (2006).
119. Lee JY, Friedman JE, Angel I, Kozak A, Koh JY: The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β-amyloid precursor protein transgenic mice. Neurobiol. Aging 25(10), 1315-1321 (2004).
120. Cherny RA, Atwood CS, Xilinas ME et al.: Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30(3), 665-676. (2001).
121. Perluigl M, Joshi G, Sultana R et al.: In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid β-peptide (1-42)-induced oxidative stress. Neuroscience 138(4), 1161-1170 (2006).
122. Ritchi CW, Bush AI, Mackinnon A et al.: Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot Phase 2 clinical trial. Arch. Neurol. 60(12), 1685-1691 (2003).
123. White AR, Du T, Laughton KM et al.: Degradation of the Alzheimer disease amyloid β-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281(26), 17670-17680 (2006).
124. Treiber C, Simons A, Strauss M et al.: Clioquinol mediates copper uptake and counteracts Cu efflux activities of the amyloid precursor protein of Alzheimer's disease. J. Biol. Chem. 279(50), 51958-51964 (2004).
125. Crouch PJ, Barnham KJ, Bush AI, White AR: Therapeutic treatments for Alzheimer's disease based on metal bioavailability. Drug News Perspect. 19(8), 469-474 (2006).
126. Van der Schyg CJ, Gal S, Geldenhuys WJ, Youdirn MB: Multifunctional neuroprotective drugs targeting monoarnine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutarnatergic action for neurodegenerative diseases. Expert Opin. Investig. Drugs 15(8), 873-886 (2006).